N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A

Targeting Protein Prenylation in Progeria

(2013) S. G. Young et al.   Science Translational Medicine

Progeria: Translational insights from cell biology

(2012) Leslie B. Gordon et al.   JOURNAL OF CELL BIOLOGY

Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development

(2012) Manoj K. Dhar et al.   New Biotechnology

Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome

(2012) L. B. Gordon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lamin A, farnesylation and aging

(2011) Sita Reddy et al.   EXPERIMENTAL CELL RESEARCH

Involvement of Akt/NF-κB pathway in N6-isopentenyladenosine-induced apoptosis in human breast cancer cells

(2010) Chiara Laezza et al.   MOLECULAR CARCINOGENESIS

Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model

(2009) Henrique Coutinho et al.   Immunity & Ageing

Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug

(2008) Maurizio Bifulco et al.   Anti-Cancer Agents in Medicinal Chemistry

N6-isopentenyladenosine inhibits cell proliferation and induces apoptosis in a human colon cancer cell line DLD1

(2008) Chiara Laezza et al.   INTERNATIONAL JOURNAL OF CANCER

Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging

(2008) Ignacio Varela et al.   NATURE MEDICINE

Phenotype and Course of Hutchinson–Gilford Progeria Syndrome

(2008) Melissa A. Merideth et al.   NEW ENGLAND JOURNAL OF MEDICINE